Q-omics provides the consensus-scored C4orf19 profile across patient tissues and cancer cell-line models. C4orf19 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C4orf19 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, C4orf19 RNA expression shows 17,106 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where C4orf19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4orf19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4orf19 survival associations across molecular data types. C4orf19 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4orf19 RNA expression–survival associations across cancer types. High C4orf19 expression shows unfavorable associations in THCA and THYM, but favorable associations in KIRC, UVM, COAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C4orf19 RNA expression.
This table summarizes C4orf19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C4orf19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4orf19 shows lower tumor expression in COAD, KIRC, HNSC, THCA, LUAD and READ. The COAD box plot shows higher C4orf19 RNA expression in normal versus tumor tissue (log2 FC = −2.131, t-test p < 0.001).
This table shows molecular features associated with C4orf19 in patient tissues and cancer cell lines. In patient samples, C4orf19 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C4orf19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
